Our Vision & Strategy
To bring individualized cancer and other therapies to market.
Build and leverage all building blocks of immunotherapy under one roof: Our technology platforms and clinical pipeline are based on 20 years of research and development.
Build a fully integrated biotech company spanning research through clinical development and manufacturing to sales and marketing.
Enter licensing, co-commercialization and co-development agreements and advance a unique go-to-market strategy.
BioNTech’s -product-to-market offering of truly individualized cancer treatments will come through its mRNA technology platform.
Lead product: IVAC® (Individualized Vaccine Against Cancer) targets cancer mutations or “neoantigens” and could therefore be universally applicable across cancer types.